Han HS - Search Results

1

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ. Kim JW, et al. Among authors: han hs, han w, han sw. Oncology. 2012;83(4):218-27. doi: 10.1159/000341359. Epub 2012 Aug 16. Oncology. 2012. PMID: 22906996

2

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ. Han HS, et al. J Korean Med Sci. 2009 Oct;24(5):910-7. doi: 10.3346/jkms.2009.24.5.910. Epub 2009 Sep 24. J Korean Med Sci. 2009. PMID: 19794992 Free PMC article.

3

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: han hs, han sw. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15. Cancer Chemother Pharmacol. 2013. PMID: 23673443

4

Weight changes after adjuvant treatment in Korean women with early breast cancer.

Han HS, Lee KW, Kim JH, Kim SW, Kim IA, Oh DY, Im SA, Bang SM, Lee JS. Han HS, et al. Breast Cancer Res Treat. 2009 Mar;114(1):147-53. doi: 10.1007/s10549-008-9984-6. Epub 2008 Mar 26. Breast Cancer Res Treat. 2009. PMID: 18365310

5

Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.

Yhim HY, Cho SH, Kim SY, Cho IS, Lee KT, Lee WS, Lee SI, Park MR, Park SG, Han HS, Choi YS, Chung IJ, Shim HJ, Lee NR, Song EK, Kim HS, Yim CY. Yhim HY, et al. Among authors: han hs. Oncol Rep. 2015 Jul;34(1):155-64. doi: 10.3892/or.2015.3954. Epub 2015 May 6. Oncol Rep. 2015. PMID: 25955097

6

Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.

Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, Kim SW, Jung S, Ro J. Park IH, et al. Among authors: han hs. Ann Oncol. 2012 Sep;23(9):2283-2289. doi: 10.1093/annonc/mds006. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377562 Free article.

7

Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia.

Choi JH, Han HS, Lee HC, Lee OJ, Kim JT, Lim SN, Lee KH, Kim ST. Choi JH, et al. Among authors: han hs. Onkologie. 2011;34(11):621-4. doi: 10.1159/000334055. Epub 2011 Oct 18. Onkologie. 2011. PMID: 22104159

8

Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.

Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Ryu MH, et al. Among authors: han hs. Eur J Cancer. 2015 Mar;51(4):482-488. doi: 10.1016/j.ejca.2014.12.015. Epub 2015 Feb 3. Eur J Cancer. 2015. PMID: 25661103 Clinical Trial.

9

Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer.

Cho HJ, Kim SJ, Kim SY, Han HS, Hong YS, Kim SH, Lim SB, Jung KH, Chang HJ, Hong EK. Cho HJ, et al. Among authors: han hs. Cancer Chemother Pharmacol. 2009 Feb;63(3):549-53. doi: 10.1007/s00280-008-0766-y. Epub 2008 May 7. Cancer Chemother Pharmacol. 2009. PMID: 18461328

10

Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH. Han HS, et al. Dis Colon Rectum. 2009 Jun;52(6):1144-51; discussion 1152-3. doi: 10.1007/DCR.0b013e31819edbf9. Dis Colon Rectum. 2009. PMID: 19581859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,487 results

Search Page

Filters